UroGen Pharma Ltd. Proceeds from Issuance of Warrants
UroGen Pharma Ltd. (URGN) reported Proceeds from Issuance of Warrants of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfWarrants · last filed 2026-08-05
- UroGen Pharma Ltd. proceeds from issuance of warrants for the quarter ending 2025-12-31 was -$3.00K.
- UroGen Pharma Ltd. proceeds from issuance of warrants for the quarter ending 2025-09-30 was $0.00.
- UroGen Pharma Ltd. proceeds from issuance of warrants for the quarter ending 2024-12-31 was $0.00.
- UroGen Pharma Ltd. proceeds from issuance of warrants for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- UroGen Pharma Ltd. proceeds from issuance of warrants for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- UroGen Pharma Ltd. proceeds from issuance of warrants for fiscal 2024 was $18.64M, a 61.72% decline from fiscal 2023.
- UroGen Pharma Ltd. proceeds from issuance of warrants for fiscal 2023 was $48.70M.
- UroGen Pharma Ltd. proceeds from issuance of warrants for fiscal 2022 was $0.00.
| Period end | Proceeds from Issuance of Warrants 3 month | Proceeds from Issuance of Warrants 6 month | Proceeds from Issuance of Warrants 9 month | Proceeds from Issuance of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$3.00K derived: sum of 2 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.00K 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $3.00K 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $18.64M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $18.64M 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $18.64M 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $48.70M derived: sum of 2 quarters · filed 2025-03-10 | $48.70M 10-K · filed 2025-03-10 | |
| 2023-09-30 | $48.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $48.70M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 10-K · filed 2024-03-14 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |